149 related articles for article (PubMed ID: 38398129)
41. Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
[TBL] [Abstract][Full Text] [Related]
42. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
43. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
[TBL] [Abstract][Full Text] [Related]
44. Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study.
Deniz M; DeGregorio A; DeGregorio N; Bekes I; Widschwendter P; Schochter F; Ernst K; Scholz C; Bauer EC; Aivazova-Fuchs V; Weissenbacher T; Kost B; Jueckstock J; Andergassen U; Steidl J; Trapp E; Fasching PA; Häberle L; Beckmann MW; Schneeweiss A; Schrader I; Janni W; Rack B; Friedl TW
Breast; 2019 Apr; 44():81-89. PubMed ID: 30690254
[TBL] [Abstract][Full Text] [Related]
45. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
46.
Incorvaia L; Fanale D; Bono M; Calò V; Fiorino A; Brando C; Corsini LR; Cutaia S; Cancelliere D; Pivetti A; Filorizzo C; La Mantia M; Barraco N; Cusenza S; Badalamenti G; Russo A; Bazan V
Ther Adv Med Oncol; 2020; 12():1758835920975326. PubMed ID: 33403015
[TBL] [Abstract][Full Text] [Related]
47. Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
Miller RS; Mokiou S; Taylor A; Sun P; Baria K
Breast Cancer Res Treat; 2022 May; 193(1):83-94. PubMed ID: 35194731
[TBL] [Abstract][Full Text] [Related]
48. Differences in age at diagnosis of ovarian cancer for each
Sekine M; Enomoto T; Arai M; Den H; Nomura H; Ikeuchi T; Nakamura S;
J Gynecol Oncol; 2022 Jul; 33(4):e46. PubMed ID: 35557031
[TBL] [Abstract][Full Text] [Related]
49. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J; Fasching PA; Couch FJ; Delaloge S; Labidi-Galy I; O'Shaughnessy J; Park YH; Eisen AF; You B; Bourgeois H; Gonçalves A; Kemp Z; Swampillai A; Jankowski T; Sohn JH; Poddubskaya E; Mukhametshina G; Aksoy S; Timcheva CV; Park-Simon TW; Antón-Torres A; John E; Baria K; Gibson I; Gelmon KA;
Breast Cancer Res Treat; 2024 Apr; 204(2):237-248. PubMed ID: 38112922
[TBL] [Abstract][Full Text] [Related]
50. Effects of
Pogoda K; Niwińska A; Sarnowska E; Nowakowska D; Jagiełło-Gruszfeld A; Siedlecki J; Nowecki Z
J Oncol; 2020; 2020():8545643. PubMed ID: 32322271
[TBL] [Abstract][Full Text] [Related]
51. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012
[TBL] [Abstract][Full Text] [Related]
52. Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8
Lee JM; Botesteanu DA; Tomita Y; Yuno A; Lee MJ; Kohn EC; Annunziata CM; Matulonis U; MacDonald LA; Nair JR; Macneill KM; Trepel JB
Oncol Lett; 2019 Oct; 18(4):3914-3924. PubMed ID: 31516602
[TBL] [Abstract][Full Text] [Related]
53. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
54. Prevalence and clinical significance of pathogenic germline
Hu X; Yang D; Li Y; Li L; Wang Y; Chen P; Xu S; Pu X; Zhu W; Deng P; Ye J; Zhang H; Lizaso A; Liu H; Mao X; Huang H; Chu Q; Hu C
Cancer Biol Med; 2019 Aug; 16(3):556-564. PubMed ID: 31565484
[TBL] [Abstract][Full Text] [Related]
55. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
[TBL] [Abstract][Full Text] [Related]
56. Prognostic disparities in young patients based on breast cancer subtype: A population-based study from the SEER database.
Chen B; Zhang X; Liu Y; Wang C
Medicine (Baltimore); 2023 Mar; 102(13):e33416. PubMed ID: 37000095
[TBL] [Abstract][Full Text] [Related]
57. The role of BRCA status on prognosis in patients with triple-negative breast cancer.
Xie Y; Gou Q; Wang Q; Zhong X; Zheng H
Oncotarget; 2017 Oct; 8(50):87151-87162. PubMed ID: 29152070
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
59. Survival Outcomes and Efficacy of Platinum in Early Breast Cancer Patients with Germline BRCA1 or BRCA2 Mutation: A Multicenter Retrospective Cohort Study.
Chen X; Qian X; Xiao M; Zhang P
Breast Cancer (Dove Med Press); 2023; 15():671-682. PubMed ID: 37692097
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast Cancer.
Bukamal Z; AlRayes A
Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
